GB201619648D0 - Novel antibodies and uses thereof - Google Patents

Novel antibodies and uses thereof

Info

Publication number
GB201619648D0
GB201619648D0 GBGB1619648.7A GB201619648A GB201619648D0 GB 201619648 D0 GB201619648 D0 GB 201619648D0 GB 201619648 A GB201619648 A GB 201619648A GB 201619648 D0 GB201619648 D0 GB 201619648D0
Authority
GB
United Kingdom
Prior art keywords
novel antibodies
antibodies
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1619648.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alligator Bioscience AB
Original Assignee
Alligator Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience AB filed Critical Alligator Bioscience AB
Priority to GBGB1619648.7A priority Critical patent/GB201619648D0/en
Publication of GB201619648D0 publication Critical patent/GB201619648D0/en
Priority to CA3044339A priority patent/CA3044339A1/en
Priority to EP17811475.7A priority patent/EP3541844A2/en
Priority to MX2019005911A priority patent/MX2019005911A/es
Priority to RU2019116624A priority patent/RU2019116624A/ru
Priority to US16/461,544 priority patent/US11535678B2/en
Priority to AU2017360094A priority patent/AU2017360094B2/en
Priority to BR112019010265A priority patent/BR112019010265A2/pt
Priority to NZ754051A priority patent/NZ754051A/en
Priority to PCT/EP2017/079930 priority patent/WO2018091740A2/en
Priority to JP2019527232A priority patent/JP7068303B2/ja
Priority to IL266738A priority patent/IL266738B2/en
Priority to KR1020197015905A priority patent/KR102679632B1/ko
Priority to CN201780071444.6A priority patent/CN109963873B/zh
Priority to US16/514,374 priority patent/US10689454B2/en
Priority to US18/054,373 priority patent/US20230295325A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1619648.7A 2016-11-21 2016-11-21 Novel antibodies and uses thereof Ceased GB201619648D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1619648.7A GB201619648D0 (en) 2016-11-21 2016-11-21 Novel antibodies and uses thereof
CN201780071444.6A CN109963873B (zh) 2016-11-21 2017-11-21 新颖抗cd137抗体和其用途
AU2017360094A AU2017360094B2 (en) 2016-11-21 2017-11-21 Novel anti_CD137 antibodies and uses thereof
NZ754051A NZ754051A (en) 2016-11-21 2017-11-21 Novel antibodies and uses thereof
MX2019005911A MX2019005911A (es) 2016-11-21 2017-11-21 Anticuerpos anti_cd137 novedosos y usos de estos.
RU2019116624A RU2019116624A (ru) 2016-11-21 2017-11-21 Новые анти_cd137 антитела и их применение
US16/461,544 US11535678B2 (en) 2016-11-21 2017-11-21 Anti-CD137 antibodies and uses thereof
CA3044339A CA3044339A1 (en) 2016-11-21 2017-11-21 Anti-cd137 antibodies and uses thereof
BR112019010265A BR112019010265A2 (pt) 2016-11-21 2017-11-21 anticorpos anti_cd137 inovadores e usos dos mesmos
EP17811475.7A EP3541844A2 (en) 2016-11-21 2017-11-21 Novel anti_cd137 antibodies and uses thereof
PCT/EP2017/079930 WO2018091740A2 (en) 2016-11-21 2017-11-21 Novel antibodies and uses thereof
JP2019527232A JP7068303B2 (ja) 2016-11-21 2017-11-21 新規抗ｃｄ１３７抗体およびその使用
IL266738A IL266738B2 (en) 2016-11-21 2017-11-21 Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer
KR1020197015905A KR102679632B1 (ko) 2016-11-21 2017-11-21 신규한 항_cd137 항체 및 이의 용도
US16/514,374 US10689454B2 (en) 2016-11-21 2019-07-17 Anti-CD137 antibodies and uses thereof
US18/054,373 US20230295325A1 (en) 2016-11-21 2022-11-10 Novel anti-cd137 antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1619648.7A GB201619648D0 (en) 2016-11-21 2016-11-21 Novel antibodies and uses thereof

Publications (1)

Publication Number Publication Date
GB201619648D0 true GB201619648D0 (en) 2017-01-04

Family

ID=57993708

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1619648.7A Ceased GB201619648D0 (en) 2016-11-21 2016-11-21 Novel antibodies and uses thereof

Country Status (14)

Country Link
US (3) US11535678B2 (enExample)
EP (1) EP3541844A2 (enExample)
JP (1) JP7068303B2 (enExample)
KR (1) KR102679632B1 (enExample)
CN (1) CN109963873B (enExample)
AU (1) AU2017360094B2 (enExample)
BR (1) BR112019010265A2 (enExample)
CA (1) CA3044339A1 (enExample)
GB (1) GB201619648D0 (enExample)
IL (1) IL266738B2 (enExample)
MX (1) MX2019005911A (enExample)
NZ (1) NZ754051A (enExample)
RU (1) RU2019116624A (enExample)
WO (1) WO2018091740A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112210010A (zh) * 2017-01-06 2021-01-12 优特力克斯有限公司 抗-人4-1bb抗体及其应用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc anticorpos anti-cd137 e métodos de uso dos mesmos
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
BR112020001441A2 (pt) 2017-08-01 2020-08-04 Eli Lilly And Company anticorpos anti-cd137
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
US12037406B2 (en) 2018-03-23 2024-07-16 Eli Lilly And Company Anti-CD137 antibodies for combination with anti-PD-L1 antibodies
GB201811408D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
CN112423845B (zh) 2018-07-12 2024-07-30 F-星治疗有限公司 结合pd-l1和cd137的抗体分子
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
CA3106048A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
AU2019312200B2 (en) 2018-07-23 2024-11-14 Heidelberg Pharma Research Gmbh Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapy
EP3835321A4 (en) * 2018-08-10 2022-11-02 Chugai Seiyaku Kabushiki Kaisha ANTI-CD137 ANTIGEN-BINDING MOLECULE AND USE THEREOF
BR112021004698A2 (pt) * 2018-09-12 2021-06-01 Eucure (Beijing) Biopharma Co., Ltd anticorpos anti-tnfrsf9 e usos dos mesmos
CN113382752B (zh) * 2019-01-02 2025-03-04 Qlsf生物治疗药物公司 Cd137激动剂抗体及其用途
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
CA3144617A1 (en) * 2019-06-26 2020-12-30 Ap Biosciences, Inc. Antibodies for t-cell activation
JP7432716B2 (ja) * 2019-11-13 2024-02-16 合肥瀚科邁博生物技術有限公司 ヒト４－１ｂｂに結合可能な分子及びその応用
JP2023509516A (ja) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
WO2021170067A1 (zh) * 2020-02-28 2021-09-02 上海复宏汉霖生物技术股份有限公司 抗cd137构建体及其用途
WO2021236658A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
US20230242658A1 (en) * 2020-06-30 2023-08-03 Nona Biosciences (Suzhou) Co., Ltd. 4-1bb-binding protein and use thereof
EP4276111A4 (en) * 2021-01-08 2025-04-30 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody
EP4355780A1 (en) 2021-06-18 2024-04-24 Alligator Bioscience AB Novel combination therapies and uses thereof
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024061364A1 (zh) * 2022-09-22 2024-03-28 成都盛世君联生物技术有限公司 一种抗4-1bb纳米抗体及其制备和应用
CN116162162B (zh) * 2022-12-19 2025-05-27 首都医科大学附属北京胸科医院 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用
CN116041517B (zh) * 2022-12-19 2025-02-25 首都医科大学附属北京胸科医院 一种抗人cd137抗体及其应用
CN116271009A (zh) * 2023-01-13 2023-06-23 深圳市乐土生物医药有限公司 含有CpG佐剂和4-1BB抗体的药物组合物及其用途
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
JP5496669B2 (ja) 2006-09-01 2014-05-21 ジェンティセル リンパ除去化合物、および抗原配列を含みかつプロフェッショナル抗原提示細胞をターゲットとする分子を含んでなる、特異的ｃｔｌ応答を誘発する組成物
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
EP3258959A4 (en) * 2015-02-22 2018-10-17 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
RU2017142008A (ru) 2015-05-21 2019-06-24 Эллигейтор Биосайенс Аб Новые полипептиды

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112210010A (zh) * 2017-01-06 2021-01-12 优特力克斯有限公司 抗-人4-1bb抗体及其应用
CN112210010B (zh) * 2017-01-06 2023-12-05 优特力克斯有限公司 抗-人4-1bb抗体及其应用

Also Published As

Publication number Publication date
MX2019005911A (es) 2019-07-08
US11535678B2 (en) 2022-12-27
KR20190086691A (ko) 2019-07-23
US20190352414A1 (en) 2019-11-21
AU2017360094B2 (en) 2024-12-12
EP3541844A2 (en) 2019-09-25
JP7068303B2 (ja) 2022-05-16
CN109963873B (zh) 2023-12-26
CN109963873A (zh) 2019-07-02
RU2019116624A3 (enExample) 2021-01-29
RU2019116624A (ru) 2020-12-21
IL266738A (en) 2019-07-31
CA3044339A1 (en) 2018-05-24
AU2017360094A1 (en) 2019-06-20
IL266738B2 (en) 2024-06-01
WO2018091740A3 (en) 2018-06-28
US20190352411A1 (en) 2019-11-21
US20230295325A1 (en) 2023-09-21
KR102679632B1 (ko) 2024-06-28
JP2020501531A (ja) 2020-01-23
WO2018091740A2 (en) 2018-05-24
US10689454B2 (en) 2020-06-23
IL266738B1 (en) 2024-02-01
BR112019010265A2 (pt) 2019-09-17
NZ754051A (en) 2023-05-26

Similar Documents

Publication Publication Date Title
IL324062A (en) Anti-CD73 antibodies and their uses
IL285375B2 (en) IL-8-binding antibodies and their uses
IL283321A (en) Antibodies against muc16 and their uses
ZA202102905B (en) Anti-galectin-9 antibodies and uses thereof
IL266738A (en) Novel antibodies and their uses
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and their uses
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL258284A (en) Anti-Lag 3 antibodies and their uses
SG11201808632YA (en) Anti-pacap antibodies and uses thereof
IL257263A (en) Antibodies against angptl8 and their use
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
IL269134A (en) Antibodies against PAR2 and their use
IL254954B (en) Anti-pacap antibodies and their uses
IL273157A (en) Antibodies specific to AXL and their uses
IL272476A (en) Anti-Apelin antibodies and their uses
PT3292154T (pt) Anticorpos anti-her3 humano e seus usos
IL266082A (en) Anti-chikv antibodies and their use
IL266049A (en) Antibodies against o1 and their uses
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
IL264417A (en) Anti-o2 antibodies and their uses
GB201712032D0 (en) Antibodies and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)